CLAIM AMENDMENTS

1 **(Cancelled)**

2. **(Currently amended)** The method of claim 20, wherein the ~~composition comprises~~ alloactivated lymphocytes ~~from at least two~~ in the composition come entirely from human donors different from the patient.

3. **(Previously presented)** The method of claim 2, wherein the composition comprises alloactivated lymphocytes from at least three human donors different from the patient.

4. **(Previously presented)** The method of claim 2, wherein the composition comprises alloactivated lymphocytes from at least four human donors different from the patient.

5. **(Previously presented)** The method of claim 20, wherein the composition comprises lymphocytes from the patient that have been inactivated.

6. **(Cancelled)**

7. **(Currently amended)** The method of claim 22, wherein the tumor-associated antigen is expressed on ~~a tumor cell~~ inactivated tumor cells present in the composition.

8. **(Previously presented)** The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with human cells ex vivo expressing HLA-DR antigens that are allogeneic to both HLA-DR antigens on the lymphocytes.

9. **(Previously presented)** The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells ex vivo for a time whereby the lymphocytes become sufficiently alloactivated to be effective in eliciting an anti-tumor immunological response when administered to a human.

10. **(Previously presented)** The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells ex vivo for a time whereby the lymphocytes become sufficiently alloactivated to be effective in extending life expectancy or causing progressive reduction in tumor mass when administered to a human having a tumor.

11. **(Previously presented)** The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells ex vivo until about the time when secretion of IFN-γ by the alloactivated lymphocytes is highest.

12. **(Previously presented)** The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells ex vivo until about the time when secretion of IL-2 by the alloactivated lymphocytes is highest.

13. **(Previously presented)** The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells ex vivo for between about 12 hours and 5 days.

14. **(Previously presented)** The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells ex vivo for between about 24 and 72 hours.

15. **(Cancelled)**

16. **(Cancelled)**

17. **(Cancelled)**

18. **(Previously presented)** The method of claim 20, wherein the composition is administered using ultrasound guided endoscopy.

19. **(Currently amended)** A method for treating cancer in a human patient, comprising administering to the patient a pharmaceutical composition comprising alloactivated lymphocytes from ~~a donor who is unrelated~~ two or more donors who are unrelated to the patient , in a compatible pharmaceutical excipient.

20. **(Currently amended)** A method for eliciting an anti-tumor immunological response in a human patient who has cancer, comprising administering to the patient a pharmaceutical composition comprising alloactivated lymphocytes from ~~a donor who is unrelated~~ two or more donors who are unrelated to the patient , in a compatible pharmaceutical excipient.

21. **(Currently amended)** A method for treating cancer in a human patient, comprising administering to the patient a pharmaceutical composition comprising ~~stimulated~~ lymphocytes allogeneic to the patient and a tumor associated antigen in a compatible pharmaceutical excipient.

22. **(Currently amended)** A method for eliciting an anti-tumor immunological response in a human patient who has cancer, comprising administering to the patient a pharmaceutical composition comprising ~~stimulated~~ lymphocytes allogeneic to the patient and a tumor associated antigen in a compatible pharmaceutical excipient.

23. **(Original)** The method of claim 19, wherein the pharmaceutical composition is administered at or around the site of a solid tumor in the patient.

24. **(Original)** The method of claim 21, wherein the pharmaceutical composition is administered at a site distal to the tumor.

25. **(Cancelled)**

26. **(Previously presented)** The method of claim 22, wherein the composition is formulated for subcutaneous or intramuscular administration, wherein administration of the composition at a site distal to the tumor elicits an immunological response by the patient against the tumor.

27. **(New)** The method of claim 22, wherein the composition was prepared using a process comprising the following steps:

a) obtaining lymphocytes from a donor who is different from the patient;

b) stimulating the donor lymphocytes in vitro; and

c) combining the stimulated lymphocytes with a tumor associated antigen and a pharmaceutical excipient.

28. **(New)** The method of claim 27, wherein step b) comprises combining the donor lymphocytes with lymphocytes from a different donor.

29. **(New)** The method of clam 28, wherein step b) further comprises culturing the lymphocytes from the two donors together so that the lymphocytes become alloactivated.

30. **(New)** The method of clam 7, wherein the tumor cells have been obtained from the patient being treated.

31. **(New)** The method of claim 7, wherein the tumor cells have been obtained from a donor different from the patient.